POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

BackgroundSquamous carcinoma of the anal canal (SCAC) is a human papillomavirus (HPV)-driven cancer with poor prognosis in locally advanced or recurrent settings. Carboplatin–paclitaxel is the preferred first-line regimen for unresectable locally advanced or metastatic SCAC, with the reported median...

Full description

Bibliographic Details
Main Authors: Sheela Rao, Mark Jones, Jill Bowman, Chuan Tian, Jean-Philippe Spano
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
anal cancer
carboplatin
paclitaxel
retifanlimab
squamous carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.935383/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.935383/full

Similar Items